Related Experiment Video
Updated: Jun 13, 2026
08:40
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Viral hepatitis and inflammatory bowel disease
Jason K Hou1, Fernando Velayos, Norah Terrault
1Baylor College of Medicine, Houston, Texas, USA.
Inflammatory Bowel Diseases
|May 19, 2010
Summary
Inflammatory bowel disease (IBD) patients with viral hepatitis require careful management. Vaccination and prophylaxis are crucial for hepatitis B virus (HBV) and hepatitis C virus (HCV) to prevent reactivation during immunosuppression.
Area of Science:
- Hepatology
- Gastroenterology
- Immunology
Background:
- Viral hepatitis, including hepatitis B virus (HBV) and hepatitis C virus (HCV), is prevalent globally and in the United States.
- Inflammatory bowel disease (IBD) patients often require immunosuppressive therapy, increasing their risk of viral hepatitis complications.
- HBV reactivation and new HBV infection pose significant risks to IBD patients undergoing immunosuppression.
Purpose of the Study:
- To review the management strategies for IBD patients with viral hepatitis.
- To highlight the importance of HBV vaccination and prophylaxis in IBD patients.
- To discuss the safety and efficacy of treatments for HBV and HCV in the context of IBD.
Main Methods:
- Literature review of studies on viral hepatitis management in IBD patients.
- Analysis of treatment guidelines for HBV and HCV in immunosuppressed populations.
- Evaluation of the impact of immunosuppressive therapies on viral hepatitis reactivation and progression.
Main Results:
- Active chronic hepatitis B virus (HBV) in IBD patients with active disease warrants HBV treatment.
- HBV reactivation is a serious risk associated with immunosuppression in IBD patients.
- Vaccination against HBV and prophylaxis for reactivation are recommended before immunosuppressive therapy.
- HCV management requires individualized treatment decisions, considering potential gastrointestinal side effects of therapies like peg-interferon and ribavirin.
Conclusions:
- Proactive management, including vaccination and prophylaxis, is essential for IBD patients with viral hepatitis.
- Treatment decisions for viral hepatitis in IBD patients must be individualized based on disease activity, viral type, and planned immunosuppression.
- Close monitoring and tailored therapeutic approaches can mitigate risks and improve outcomes for IBD patients with viral hepatitis.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Related Concept Videos
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...